EmVenio Research has announced a partnership with TrialHub. Through TrialHub's data intelligence gathering platform, EmVenio can identify optimal markets to attract clinical trial participants who are needed to support pharmaceutical sponsors and clinical research organizations' participation goals.
TrialHub's benchmarking and data provide a feasibility overview of the clinical research landscape, allowing EmVenio to strategically select clinical trial site locations based on disease prevalence, recruitment rates, and access to readily available healthcare facilities and practitioners, including underserved communities.
By working with TrialHub, EmVenio will donate a full patient scholarship to the European Patients' Academy on Therapeutic Innovation's Patient Expert program. EUPATI's program focuses on education, inclusivity and stakeholder partnership to enhance patient engagement through accessible and innovative education.
EmVenio Research and TrialHub partner to optimize patient participation and accelerate site selection for clinical trials. (2023, July 27). Cision PR Newswire.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Novel Agent Shows Superiority Over Placebo in Reducing Monthly Migraine Days
September 5th 2024Lu AG09222 shows promise as first-in-class medication that prevents neurogenic inflammation, vasodilation, and parasympathetic lacrimation, which are considered to be surrogate markers of migraine attacks.